GLPwatch
Papers (12034)
Page 143 of 201, ranked by citation count.
- GLP-1 receptor agonism and GIP receptor antagonism induce substantial alterations in enteroendocrine and islet cell populations in obese high fat fed mice.
- A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol.
- Managing diabetes in patients with diabetes of long duration.
- Design of Auto-Adaptive Drug Delivery System for Effective Delivery of Peptide Drugs to Overcoming Mucus and Epithelial Barriers.
- Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database.
- A software interface for in silico testing of type 2 diabetes treatments.
- A Spectroscopic and Molecular Dynamics Study on the Aggregation Properties of a Lipopeptide Analogue of Liraglutide, a Therapeutic Peptide against Diabetes Type 2.
- Exenatide enhances kaliuresis under conditions of hyperkalemia.
- Two cases of type 2 diabetes mellitus in elderly patients successfully treated with monthly exenatide long-acting release.
- Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.
- Effect of Semaglutide on C-peptide levels in patients with type 2 diabetes.
- Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction.
- Impact of GLP-1 and GLP-1/GIP agonists on healthcare resource utilization in individuals with scarring alopecias: A retrospective cohort analysis using TriNetX.
- The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials.
- Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.
- Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
- Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.
- Effects of GLP-1 Receptor Agonist on Glycolipid Metabolism and Micro Inflammatory Status in Patients with Abdominal Obesity and Type 2 Diabetes.
- An Open-Label, Single-Center Proof of Concept Study Evaluating the Efficacy and Safety of Tirzepatide for Moderate to Severe Hidradenitis Suppurativa.
- Efficacy and tolerability of liraglutide in combination with other antidiabetic drugs in type 2 diabetes.
- Pre-immunization of diet-induced obese male mice with inactivated pathogens increases power in a liraglutide intervention study.
- Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
- Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials.
- Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice.
- Liraglutide in islet transplantation: from bench to bedside.
- Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial.
- Shedding light on weight loss: A narrative review of medications for treating obesity.
- Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.
- GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: A Narrative Review.
- Assessment of innate immune response modulating impurities (IIRMI) in synthetic peptide drugs (liraglutide).
- The Sit Less, Interact and Move More (SLIMM-2) Trial: Protocol for a randomized control trial of a sedentary behavior intervention, resistance training and semaglutide on sedentary behavior in persons with chronic kidney disease.
- GABA and GLP-1 receptor agonist combination therapy modifies diabetes and Langerhans islet cytoarchitecture in a rat model of Wolfram syndrome.
- Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.
- Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.
- In adults with moderate-to-severe OSA and obesity, tirzepatide reduced apnea-hypopnea events vs. placebo.
- Improved Clinical Outcomes with Dulaglutide as Add-on Medication to Oral Antidiabetic Drugs with or Without Insulin in Overweight Indian Patients with Type 2 Diabetes Mellitus: Retrospective Study in a Real-World Setting.
- [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
- Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data.
- [The protective effect of exenatide on the renal injury in diabetic rats].
- No More Needles: Oral Semaglutide for Weight Loss.
- Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.
- Erratum. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37:2159-2167.
- Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach.
- Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews.
- Impact of GLP-1 receptor agonists on cardiovascular outcomes in patients with peripheral artery disease without diabetes: A propensity score-matched analysis.
- Adherence and Effectiveness of Liraglutide in Adolescents with Obesity.
- Putting More Weight on Obesity Trials in Heart Failure.
- In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk.
- Evaluating Suicidal Risk in GLP-1RA Therapy: An Umbrella Review of Meta-Analytic Evidence.
- Combined effect of continuous glucose monitoring and semaglutide: analysis of administrative claims.
- Semaglutide vs Tirzepatide Dosages for Weight Loss.
- Patient Experience With The Single-Use Pen For Injection of Once Weekly Dulaglutide in Injection-Naive Patients With Type 2 Diabetes.
- Incretin-Based Therapies and Post-Bariatric Surgery Alcohol Use Disorder.
- INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6-month treatment with incretin-based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double-blind, randomised controlled trials (INVESTDIA).
- Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice.
- The global clinical trial landscape for non-alcoholic fatty liver disease (NAFLD): current status and future prospects.
- Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.
- Neurological outcomes of antidiabetic therapy: What the neurologist should know.
- Exendin-4 Exacerbates Burn-Induced Mortality in Mice by Switching to Th2 Response.
- Dulaglutide for erectile dysfunction in type 2 diabetes.